Comparison of Gefitinib in the treatment of patients with non-small cell lung cancer and clinical effects of Osimertinib and EGFR Gene mutation

Xiaofeng Li; Zhanqiang Zhai; Youcai Zhu; Haiou Zhou

doi:10.12669/pjms.38.6.5456

Comparison of Gefitinib in the treatment of patients with non-small cell lung cancer and clinical effects of Osimertinib and EGFR Gene mutation

Pak J Med Sci. 2022 Jul-Aug;38(6):1589-1594. doi: 10.12669/pjms.38.6.5456.

Authors

Xiaofeng Li¹, Zhanqiang Zhai², Youcai Zhu³, Haiou Zhou⁴

Affiliations

¹ Xiaofeng Li Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, 309 Shuangyuan Road, Jiaxing 314000, Zhejiang Province, P.R. China.
² Zhanqiang Zhai, Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, 309 Shuangyuan Road, Jiaxing 314000, Zhejiang Province, P.R. China.
³ Youcai Zhu, Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, 309 Shuangyuan Road, Jiaxing 314000, Zhejiang Province, P.R. China.
⁴ Haiou Zhou, Department of Anesthesiology, Zhejiang Rongjun Hospital, 309 Shuangyuan Road, Jiaxing 314000, Zhejiang Province, P.R. China.

Abstract

Objectives: To compare the clinical effects of Osimertinib and Gefitinib in the treatment of non-small cell lung (NSCLC) complicated with epidermal growth factor receptor (EGFR) gene mutation.

Methods: We retrospectively analyzed the clinical data of 102 patients with advanced NSCLC and EGFR gene mutations treated in the Chest Disease Diagnosis and Treatment Center of our hospital from January 2018 to January 2020. We divided the data based on the administered treatments into Osimertinib and Gefitinib groups. The disease control rate (DCR), progression free survival (PFS) and the incidence of adverse events in both groups were analyzed.

Results: In the Osimertinib group, there was one patients with complete response (CR), 38 with partial response (PR), eight with stable disease (SD), and two with progressive disease (PD)/ The overall response rate (ORR) was 79.59% (39/49), and the disease control rate (DCR) was 95.92% (47/49). In the Gefitinib group, we found zero patients with CR, 37 patients with PR, 11 with SD, and five with PD. The ORR in the Gefitinib group was 69.80% (37/53) and DCR was 90.57% (48/53). There was no statistical significance between the two groups, ORR was Χ²=0.927 (P=0.336) and the DCR Χ²=0.221 (P=0.638). The median PFS of and Gefitinib groups was significantly higher in the oxitinib group, compared to the Gefitinib group (18.1 months (95% CI 15.4-20.7) and 10.7 months (95% CI 9.9-11.4), respectively, P<0.001). The incidence of adverse reactions in the Osimertinib group was 12.24% (6/49), which was significantly lower than 28.30% (15/53) in the Gefitinib group (P < 0.05).

Conclusions: The clinical effect of oxitinib in the treatment of non-small cell lung cancer complicated with EGFR gene mutation is similar to that of Gefitinib. In patients with advanced NSCLC and EGFR gene mutations, oxitinib treatment is associated with significantly longer PFS and lower adverse reaction rate compared with Gefitinib treatment.

Keywords: Epidermal growth factor receptor; Gefitinib; Non-small cell lung cancer; Osimertinib; Targeted therapy.